Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
eli lilly
17
×
fda
17
×
life sciences
national blog main
raleigh-durham blog main
17
×
boston top stories
indiana blog main
new york blog main
raleigh-durham top stories
san diego blog main
san francisco blog main
seattle blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana top stories
national
national top stories
new york top stories
san diego top stories
san francisco top stories
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
amgen
startups
cancer
pfizer
bristol-myers squibb
deals
glaxosmithkline
medicare
allergan
cancer immunotherapy
What
bio
roundup
drug
fda
new
companies
drugs
week
won
approval
crispr
days
life
migraine
pharmaceutical
science
alzheimer’s
annual
big
biotech
black
class
congress
decades
diabetes
diamond’s
eli
fallout
giant
growing
known
moves
news
notes
pharma
price
thanks
time
acute
addresses
Language
unset
Current search:
fda
×
" eli lilly "
×
" raleigh-durham blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines